33 Acute Myeloid Leukemia Clinical Trials in New York, NY (2026)

Q: Are there acute myeloid leukemia clinical trials in New York?

Yes, there are 33 acute myeloid leukemia clinical trials currently recruiting in New York, NY.

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Q: Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Acute Myeloid Leukemia Studies in New York

NCT06976736Recruiting

A Long Term Follow-up Study of TScan TCR-T Products

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored f...

New York, NY1,000 participantsTScan Therapeutics, Inc.

View Study Details

NCT06163430Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with pr...

New York, NYPHASE1330 participantsTerns, Inc.

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

New York, NYPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

New York, NYPHASE1300 participantsOrca Biosystems, Inc.

View Study Details

NCT06656494Recruiting

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes....

New York, NYPHASE1266 participantsBeijing InnoCare Pharma Tech Co., Ltd.

View Study Details

NCT05304377Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and with...

New York, NYPHASE1250 participantsEnliven Therapeutics

View Study Details

NCT06366789Recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute Myeloid Le...

New York, NYPHASE1150 participantsLomond Therapeutics Holdings, Inc.

View Study Details

NCT06824168Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...

New York, NYPHASE2130 participantsDaiichi Sankyo

View Study Details

NCT06533761Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effi...

New York, NYPHASE1125 participantsStelexis BioSciences

View Study Details

NCT02781883Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with ...

New York, NYPHASE2108 participantsBio-Path Holdings, Inc.

View Study Details

NCT04243785Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory...

New York, NYPHASE180 participantsEdgewood Oncology Inc.

View Study Details

NCT07566377Recruiting

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer....

New York, NYPHASE271 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06846606Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinica...

New York, NYPHASE169 participantsAuron Therapeutics, Inc.

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

New York, NYPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT05884333Recruiting

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includ...

New York, NYPHASE254 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04838041Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have...

New York, NYPHASE251 participantsMedical College of Wisconsin

View Study Details

NCT04872478Recruiting

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute l...

New York, NYPHASE150 participantsMeryx, Inc.

View Study Details

NCT06146257Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or...

New York, NYPHASE148 participantsGluBio Therapeutics Inc.

View Study Details

NCT05190471Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to asses...

New York, NYPHASE148 participantsBio-Path Holdings, Inc.

View Study Details

NCT07012044Recruiting

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of impr...

New York, NYPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT07392242Recruiting

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment...

New York, NYPHASE245 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05748197Recruiting

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that ...

New York, NYPHASE140 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07320235Recruiting

Imetelstat Combinations in Relapsed AML

IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML. The tr...

New York, NYPHASE136 participantsDouglas Tremblay

View Study Details

NCT04925479Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...

New York, NYPHASE134 participantsNovartis Pharmaceuticals

View Study Details

NCT04644016Recruiting

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related...

New York, NYPHASE231 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06773208Recruiting

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemi...

New York, NYPHASE230 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07661095Recruiting

A Study of CRD3874-SI in People With Leukemia

The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML)....

New York, NYPHASE124 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06177067Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid...

New York, NYPHASE124 participantsSt. Jude Children's Research Hospital

View Study Details

NCT07107126Recruiting

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and ...

New York, NYPHASE124 participantsRemedy Plan, Inc.

View Study Details

NCT07011004Recruiting

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side...

New York, NYPHASE118 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07486713Recruiting

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-...

New York, NYPHASE416 participantsRigel Pharmaceuticals

View Study Details

NCT06017258Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in particip...

New York, NYPHASE115 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06284486Recruiting

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML....

New York, NYPHASE18 participantsM.D. Anderson Cancer Center

View Study Details

About Acute Myeloid Leukemia Clinical Trials in New York

Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.

There are currently 33 acute myeloid leukemia clinical trials recruiting participants in New York, NY. These studies are seeking a combined 3,898 participants. Research is being sponsored by TScan Therapeutics, Inc., Terns, Inc., Taiho Oncology, Inc. and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Acute Myeloid Leukemia Clinical Trials in New York — FAQ

Are there acute myeloid leukemia clinical trials in New York?

Yes, there are 33 acute myeloid leukemia clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What acute myeloid leukemia treatments are being tested?

The 33 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov